See What HealthDay Can Do For You
Contact Us

FDA: Drug Approved for Inherited Blood Disorder

Exjade removes excess iron in blood of people with non-transfusion-dependent thalassemia

WEDNESDAY, Jan. 23 (HealthDay News) -- Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with the genetic blood disorder non-transfusion-dependent thalassemia (NTDT).

Thalassemia typically leads to the production of fewer red blood cells and less hemoglobin. NTDT is a milder form of thalassemia that, unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.

The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.

The drug is produced by Novartis, based in East Hanover, N.J.

More Information

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.